The Anticoagulant Reversal Drugs Market is expected to reach US$ 2,276.54 million by 2027 from US$ 922.55 million in 2019; the market is estimated to grow at a CAGR of 12.6% from 2020 to 2027.
Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. In medical conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome, Factor V Leiden, anticoagulant reversal drugs are used.
Various players operating in the anticoagulant reversal drugs market are developing and launching new products to expand their geographic reach and capacity to cater a large number of customers. In April 2018, Boehringer Ingelheim, a leading pharmaceutical company, received the US Food and Drug Administration (FDA) full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate mesylate). Additionally, in January 2019, AMAG Pharmaceuticals acquired Perosphere Pharmaceuticals, a private biopharmaceutical company. AMAG Pharmaceuticals, through this acquisition expanded its anticoagulant reversal ciraparantag to its portfolio. Similarly, in May 2018, Portola Pharmaceuticals received FDA approval for the rapid reversal of anticoagulation due to major bleeding. Such developments and approvals of new products are likely to favor the market growth.
Get Sample PDF:
https://www.theinsightpartners.com/sample/TIPRE00004954/
Geographically, the anticoagulant reversal drugs market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America held the largest market share in 2019. In North America, the US is the largest market for anticoagulant reversal drugs. The growth of the market in the region is attributed to the presence of key market players and their product development efforts. Additionally, the escalating prevalence of atrial fibrillation further contributes to the growth of the anticoagulant reversal drugs market in North America.
Boehringer Ingelheim International GmbH; Pfizer Inc; Octapharma AG; Amag Pharmaceuticals, Inc; Fresenius Kabi AG; Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals); CSL Limited; China Biologic Products, Inc; Grifols, S.A; and Shanghai RAAS Blood Products Co., Ltd are among the key companies in the anticoagulant reversal drugs market.
Buy Now: https://www.theinsightpartners.com/sample/TIPRE00004954/
The report analyzes anticoagulant reversal drugs market as follows:
- Prothrombin Complex Concentrates
- Vitamin K
- Protamine
- Tranexamic Acid
- Idarucizumab
- AndeXXa
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
